Angiotensin II
FDA-approved IV (into a vein) angiotensin II for shock (Giapreza).
What it's for
FDA-approved IV (into a vein) angiotensin II for shock (Giapreza).
What it's for
Angiotensin II is the endogenous 8–amino-acid peptide of the renin–angiotensin system; Giapreza is a synthetic IV (into a vein) formulation. It increases blood pressure in adults with septic or other distributive shock.
What it does for the body
It increases blood pressure in adults with septic or other distributive shock. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
AT1 receptors (lock-and-key landing spots on cells) activating its target pathway causes arterial blood-vessel tightening and aldosterone release, raising mean arterial pressure. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Angiotensin II has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Angiotensin II — FDA.gov search
- ClinicalTrials.gov search: Angiotensin II — U.S. clinical trials registry
- Drugs@FDA search: Angiotensin II — FDA drug database (if approved)
- PubMed search: Angiotensin II — NCBI PubMed
- PubMed Central search: Angiotensin II — NCBI PMC